Walleye Trading
CRNX icon

Walleye Trading’s Crinetics Pharmaceuticals CRNX Stock Holding History

Walleye Trading’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,800
Closed -$84.3K – 4386
2024
Q1 		$84.3K Buy
+1,800
New +$70.4K ﹤0.01% 3837
2023
Q4 		– Sell
-9,900
Closed -$294K – 5130
2023
Q3 		$294K Buy
+9,900
New +$204K ﹤0.01% 3368

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Walleye Trading's CRNX Position: Q1 2024 in Review

Walleye Trading sold out of Crinetics Pharmaceuticals (CRNX) in Q1 2024, closing a stake of 19,290 shares — an estimated $755K sold.

Walleye Trading first reported a position in CRNX in Q3 2022 and held it in 6 quarters. The position peaked at $1.84M in Q3 2023. 203 funds tracked by Wall St. Rank hold CRNX as of Q1 2024.

  • Walleye Trading reported no remaining Crinetics Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Walleye Trading sold 19,290 Crinetics Pharmaceuticals shares in Q1 2024, an estimated $755K.
  • Walleye Trading first reported a position in Crinetics Pharmaceuticals in Q3 2022 and held it in 6 quarters.
  • Walleye Trading's Crinetics Pharmaceuticals position peaked at $1.84M in Q3 2023.
  • 203 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2024.

Based on Walleye Trading's 13F filing for Q1 2024, filed 15 May 2024.